Peptilogics
Pittsburgh
About Peptilogics
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $122.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: peptilogics.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/peptilogics-72655 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.